UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000008579
Receipt No. R000009960
Scientific Title HER receptors regulated immunoescape from NK cell-mediated innnate immunity in non-small-cell lung cancer
Date of disclosure of the study information 2012/09/01
Last modified on 2018/03/16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title HER receptors regulated immunoescape from NK cell-mediated innnate immunity in non-small-cell lung cancer
Acronym HER receptors regulated immunoescape in non-small-cell lung cancer
Scientific Title HER receptors regulated immunoescape from NK cell-mediated innnate immunity in non-small-cell lung cancer
Scientific Title:Acronym HER receptors regulated immunoescape in non-small-cell lung cancer
Region
Japan

Condition
Condition operable cases of non-small-cell lung cancer
Classification by specialty
Chest surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 HER signaling effects on NK cell-mediated cytotoxicity in non-small-cell lung cancer
Basic objectives2 Others
Basic objectives -Others Immunological assessment
Trial characteristics_1 Confirmatory
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes Assess the effects of HER signaling on NK cell-mediated cytotoxicity in non-small-cell lung cancer
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Surgical cases of non-small-cell lung cancer in our institute
Key exclusion criteria none
Target sample size 30

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Riki Okita
Organization Kawasaki Medical School
Division name General Thoracic Surgery
Zip code
Address Matsushima 577, Kurashiki
TEL 0864621111
Email riki0716okita@yahoo.co.jp

Public contact
Name of contact person
1st name
Middle name
Last name Riki Okita
Organization Kawasaki Medical School
Division name General Thoracic Surgery
Zip code
Address Matsushima 577, Kurashiki
TEL 086-464-1124
Homepage URL
Email gts@med.kawasaki-m.ac.jp

Sponsor
Institute General Thoracic Surgery, Kawasaki Medical School
Institute
Department

Funding Source
Organization Kawasaki Medical School
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 川崎医科大学附属病院

Other administrative information
Date of disclosure of the study information
2012 Year 09 Month 01 Day

Related information
URL releasing protocol
Publication of results Partially published

Result
URL related to results and publications http://link.springer.com/article/10.1007%2Fs00262-016-1814-9
Number of participants that the trial has enrolled
Results Okita R, et al. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer. Cancer Immunol Immunother 2016.
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2012 Year 07 Month 09 Day
Date of IRB
Anticipated trial start date
2012 Year 07 Month 09 Day
Last follow-up date
2018 Year 03 Month 16 Day
Date of closure to data entry
2018 Year 03 Month 16 Day
Date trial data considered complete
2018 Year 03 Month 16 Day
Date analysis concluded
2018 Year 03 Month 22 Day

Other
Other related information case control, prospective study

Management information
Registered date
2012 Year 07 Month 31 Day
Last modified on
2018 Year 03 Month 16 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009960

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.